PMID- 29186978
OWN - NLM
STAT- MEDLINE
DCOM- 20181106
LR  - 20190201
IS  - 1535-3699 (Electronic)
IS  - 1535-3702 (Print)
IS  - 1535-3699 (Linking)
VI  - 243
IP  - 4
DP  - 2018 Feb
TI  - Association of liver cirrhosis severity with type 2 diabetes mellitus in 
      hepatocellular carcinoma.
PG  - 323-326
LID - 10.1177/1535370217744511 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a major risk factor associated with 
      hepatocellular carcinoma (HCC). However, the association of T2DM with liver 
      cirrhosis and therapy response in HCC patients is not clear. Hence, in this 
      study, we have evaluated the influence of T2DM on liver cirrhosis severity of HCC 
      and sorafenib response. HCC patients were divided in two groups: T2DM (n = 20) 
      and non-T2DM (nT2DM; n = 50). We found significantly higher number of patients in 
      T2DM group had decompensated liver disease with Child-Turcotte-Pugh score >/= 7. 
      Additionally, 71.4% patients were observed to be sorafenib sensitive in T2DM 
      group which was significantly higher as compared to 30% in nT2DM group. This 
      study has highlighted the predisposition of HCC patients with T2DM toward more 
      severe liver disease who were found to be better respondents of sorafenib. Impact 
      statement We have explored the association of type 2 diabetes mellitus (T2DM) on 
      liver cirrhosis severity along with response toward sorafenib in hepatocellular 
      carcinoma (HCC). Most HCC patients exhibit prior history of liver cirrhosis that 
      results following long span of chronic liver disease. T2DM constitutes as an 
      important risk factor for HCC development which is known to elevate its 
      incidence. Further, sorafenib is the FDA approved therapy for HCC whose 
      therapeutic outcome is not investigated in HCC patients with T2DM till date. This 
      observation-based study has unveiled a positive association between T2DM and 
      severity of liver cirrhosis as well as sorafenib response in HCC as examined in a 
      clinical setting.
FAU - Makol, Ankita
AU  - Makol A
AD  - 1 Department of Experimental Medicine and Biotechnology, Postgraduate Institute 
      of Medical Education and Research, Chandigarh 160012, India.
FAU - Kanthaje, Shruthi
AU  - Kanthaje S
AD  - 1 Department of Experimental Medicine and Biotechnology, Postgraduate Institute 
      of Medical Education and Research, Chandigarh 160012, India.
FAU - Dhiman, Radha K
AU  - Dhiman RK
AD  - 2 Department of Hepatology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh 160012, India.
FAU - Kalra, Naveen
AU  - Kalra N
AD  - 3 Department of Radio Diagnosis and Imaging, Postgraduate Institute of Medical 
      Education and Research, Chandigarh 160012, India.
FAU - Chawla, Yogesh K
AU  - Chawla YK
AD  - 2 Department of Hepatology, Postgraduate Institute of Medical Education and 
      Research, Chandigarh 160012, India.
FAU - Chakraborti, Anuradha
AU  - Chakraborti A
AD  - 1 Department of Experimental Medicine and Biotechnology, Postgraduate Institute 
      of Medical Education and Research, Chandigarh 160012, India.
LA  - eng
PT  - Journal Article
DEP - 20171129
PL  - Switzerland
TA  - Exp Biol Med (Maywood)
JT  - Experimental biology and medicine (Maywood, N.J.)
JID - 100973463
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/metabolism
MH  - Carcinoma, Hepatocellular/epidemiology/*pathology
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Liver Cirrhosis/*epidemiology/*pathology
MH  - Liver Neoplasms/epidemiology/*pathology
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/analogs & derivatives/metabolism
MH  - Phenylurea Compounds/metabolism
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Sorafenib
PMC - PMC6022924
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - cirrhosis
OT  - hepatocellular carcinoma
OT  - sorafenib
EDAT- 2017/12/01 06:00
MHDA- 2018/11/07 06:00
PMCR- 2019/02/01
CRDT- 2017/12/01 06:00
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2018/11/07 06:00 [medline]
PHST- 2017/12/01 06:00 [entrez]
PHST- 2019/02/01 00:00 [pmc-release]
AID - 10.1177_1535370217744511 [pii]
AID - 10.1177/1535370217744511 [doi]
PST - ppublish
SO  - Exp Biol Med (Maywood). 2018 Feb;243(4):323-326. doi: 10.1177/1535370217744511. 
      Epub 2017 Nov 29.